⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 17, 2024Postgraduate Medicine

Association between variants in TCF7L2 , CTRB1/2 , and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists

Artemis Kyriakidou Angeliki V. Kyriazou Theocharis Koufakis Yiannis Vasilopoulos Iakovos Avramidis S. Baltagiannis Dimitrios G. Goulis Kalliopi Kotsa

View at Publisher

Ask AI

Bookmark

Share

Abstract

Objectives The factors determining the response to treatment with glucagon-like peptide-1 receptor agonists (GLP-1- RAs) have not been clarified. The present study investigated the association between polymorphisms in TCF7L2, CTRB1/2 and GLP-1 R genes and response to GLP-1 RAs regarding glycemic control and weight loss among Greek patients with type 2 diabetes mellitus (T2DM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kyriakidou et al. (2024) studied this question.

synapsesocial.com/papers/68e78ba0b6db6435876fe1df https://doi.org/10.1080/00325481.2024.2328513

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesityreview · 2026
2Responders Vs. Non‐Responders or How to Predict the Response to GLP ‐1 or GLP ‐1/ GIP Receptor Agonist TherapyLiterature Review · 2026
3Genetic Variations in GLP-1R: Impact on Diabetes and Obesity TherapeuticsReview · 2026 · 3 citations
4Precision medicine in type 2 diabetes mellitus: Unraveling the role of TCF7L2, CTRB1/2, and GLP-1R genetic variants in response to treatment with glucagon-like peptide-1 receptor agonists2024
5Genetic predictors of GLP1 receptor agonist weight loss and side effectsOriginal Research · 2026 · 37 citations

More related papers

Independent Genetic Effects of Glucagon-like Peptide-1 Receptor Locus on Body Mass Index and Type 2 Diabetes2026
Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management2025
The Gain-of-Function <i>GLP1R</i> R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists2026

More from Postgraduate Medicine

Changes in intravenous pantoprazole utilization following two sequential interventions in a tertiary referral hospitalFri,
Identification of perioperative risk factors for retrograde type A dissection after thoracic endovascular aortic repair for type B dissectionThu,